» Articles » PMID: 2360823

Oral Ciprofloxacin Treatment of Pseudomonas Aeruginosa Osteomyelitis

Overview
Specialty Pharmacology
Date 1990 May 1
PMID 2360823
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Twenty-two adult patients with osteomyelitis due to Pseudomonas aeruginosa were enrolled in an open, prospective cooperative study to determine the efficacy of oral ciprofloxacin therapy in a dosage of 750 mg twice a day. Twenty patients received a complete course of treatment and could be assessed for efficacy. There were 12 men and 8 women, with a mean age of 55 years. Six patients had undergone previous, unsuccessful attempts at therapy. Eight patients had clinically important underlying conditions. The most common sites of infection were the sternum (six patients), hip (four patients), vertebrae (four patients), and tibia (two patients). Initial surgical debridement was performed in 18 of the 20 assessable patients. The mean duration of treatment was 2.85 months (range, 1 to 4 months), and that of the follow-up was 27 months (range, 6 to 52 months). Cure was achieved in 19 of the 20 (95%) patients. The only significant adverse effect (which prompted discontinuation of therapy) was severe nausea in one case. Oral ciprofloxacin coupled with adequate debridement is an effective, convenient, and safe therapy in patients with acute and subacute P. aeruginosa osteomyelitis.

Citing Articles

Recurrent skin opening induced by chronic sternal osteomyelitis caused by a bite wound in a cat: A case report.

Yu S, Lee S Vet Med Sci. 2024; 10(3):e1425.

PMID: 38563757 PMC: 10986631. DOI: 10.1002/vms3.1425.


Ciprofloxacin release using natural rubber latex membranes as carrier.

Dias Murbach H, Jaques Ogawa G, Borges F, Miranda M, Lopes R, de Barros N Int J Biomater. 2015; 2014:157952.

PMID: 25587278 PMC: 4283226. DOI: 10.1155/2014/157952.


Remission after treatment of osteoarticular infections due to Pseudomonas aeruginosa versus Staphylococcus aureus: a case-controlled study.

Seghrouchni K, Van Delden C, Dominguez D, Benkabouche M, Bernard L, Assal M Int Orthop. 2011; 36(5):1065-71.

PMID: 21983903 PMC: 3337090. DOI: 10.1007/s00264-011-1366-8.


Diagnosis and management of osteomyelitis. Decision analytic and pharmacoeconomic considerations.

Tavakoli M, Davey P, Clift B, Davies H Pharmacoeconomics. 2000; 16(6):627-47.

PMID: 10724791 DOI: 10.2165/00019053-199916060-00003.


Use of quinolones in osteomyelitis and infected orthopaedic prosthesis.

Lew D, Waldvogel F Drugs. 1999; 58 Suppl 2:85-91.

PMID: 10553713 DOI: 10.2165/00003495-199958002-00017.


References
1.
Scully B, Neu H, Parry M, MANDELL W . Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa. Lancet. 1986; 1(8485):819-22. DOI: 10.1016/s0140-6736(86)90937-2. View

2.
Hooper D, Wolfson J . The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother. 1985; 28(5):716-21. PMC: 176369. DOI: 10.1128/AAC.28.5.716. View

3.
Follath F, Bindschedler M, Wenk M, Frei R, Stalder H, Reber H . Use of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections. Eur J Clin Microbiol. 1986; 5(2):236-40. DOI: 10.1007/BF02013997. View

4.
Greenberg R, Kennedy D, Reilly P, Luppen K, Weinandt W, Bollinger M . Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin. Antimicrob Agents Chemother. 1987; 31(2):151-5. PMC: 174681. DOI: 10.1128/AAC.31.2.151. View

5.
Lesse A, Freer C, Salata R, Francis J, Scheld W . Oral ciprofloxacin therapy for gram-negative bacillary osteomyelitis. Am J Med. 1987; 82(4A):247-53. View